Coke is the first product to be added to the global COVID prevention and treatment plan after U.S. President Donald Trump signed an executive order that bans imports of all manufactured products that have high levels of COVID virus.
Coke is made of metallol and is one of the most abundant natural materials in the world, and the use of metallsurgical cokes for healthcare is one way the United States can protect itself from the coronavirus epidemic.
Coak is one product that is not covered by the current United States Food and Drug Administration (FDA) order because it has no use in the production of medical products.
But the coke will now be added after a meeting between the United Nations Development Program (UNDP) and the World Health Organization (WHO) to improve the global use of coke, a source told Fox News.
The WHO recently issued a joint declaration with the United Kingdom and China, which called on all countries to ensure that all coke is used for medical purposes and that COVID patients are provided with adequate access to treatment.
In its joint declaration, the WHO and the UNDP said they will work together to identify coke products that are appropriate for healthcare, including for those who are not receiving treatment in the United states, including COVID vaccine, coke sterilization and coke infusion.
Cooke is also a high-grade synthetic polymer.
Its use in healthcare is highly regulated by the WHO, and it is not a medicine.
The U.K. and China have been developing their own coke solutions for healthcare in China.
Coq is the only COVID medication currently in the U., U.N. and UN drug supply lists.
Coq is currently used for malaria, diarrhea, pneumonia and pneumonia-associated coronaviruses and is also used in treatment of other infectious diseases, such as tuberculosis and other respiratory infections.
Cozidabran, another coke treatment, is currently under development for the treatment of COVI.
The United States has a $10 million commitment to develop Coq.
In the meantime, it is encouraging U.C. Davis to begin a clinical trial to see if Coq can treat COVI patients with improved respiratory function.
The trials could begin as early as June and will take about five months.
U.C.-Davis researchers will use COVID therapy to test if the treatment improves respiratory function in patients who are unable to get adequate COVID treatment elsewhere.
Coaq also can help people who have had a COVID infection and are unable or unwilling to get COVID vaccines, according to the UCA news release.